|
1
|
Islami F, Marlow EC, Thomson B, McCullough
ML, Rumgay H, Gapstur SM, Patel AV, Soerjomataram I and Jemal A:
Proportion and number of cancer cases and deaths attributable to
potentially modifiable risk factors in the United States, 2019. CA
Cancer J Clin. 74:405–432. 2024.PubMed/NCBI
|
|
2
|
Alberg AJ, Brock MV and Samet JM:
Epidemiology of lung cancer: Looking to the future. J Clin Oncol.
23:3175–3185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schaefers C, Seidel C, Bokemeyer F and
Bokemeyer C: The prognostic impact of the smoking status of cancer
patients receiving systemic treatment and radiation therapy,
surgery: A systematic review and meta-analysis. Eur J Cancer.
172:130–137. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luo Y and Stent S: Smoking's lasting
effect on the immune system. Nature. 626:724–725. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuśnierczyk P: Genetic differences between
smokers and never-smokers with lung cancer. Front Immunol.
14:10637162023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de la Iglesia JV, Slebos RJC, Martin-Gomez
L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T,
Masannat J, et al: Effects of tobacco smoking on the tumor immune
microenvironment in head and neck squamous cell carcinoma. Clin
Cancer Res. 26:1474–1485. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Foerster B, Pozo C, Abufaraj M, Mari A,
Kimura S, D'Andrea D, John H and Shariat SF: Association of smoking
status with recurrence, metastasis, mortality among patients with
localized prostate cancer undergoing prostatectomy or radiotherapy:
A systematic review and meta-analysis. JAMA Oncol. 4:953–961. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Masui Y, Shukuya T, Kataoka S, Shiozaki H,
Kurokawa K, Nakamura I, Miyawaki T, Koinuma Y, Asao T, Kanemaru R,
et al: Second malignancy in advanced or recurrent non-small cell
lung cancer after the advent of molecular targeted drugs and
immunotherapy. Thorac Cancer. 15:2291–2297. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi SH, Chan RR and Lehto RH:
Relationships between smoking status and psychological distress,
optimism, and health environment perceptions at time of diagnosis
of actual or suspected lung cancer. Cancer Nurs. 42:156–163. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guimond AJ, Croteau VA, Savard MH, Bernard
P, Ivers H and Savard J: Predictors of smoking cessation and
relapse in cancer patients and effect on psychological variables:
An 18-Month observational study. Ann Behav Med. 51:117–127. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McLean L, Leal JL, Solomon BJ and John T:
Immunotherapy in oncogene addicted non-small cell lung cancer.
Transl Lung Cancer Res. 10:2736–2751. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun LY, Cen WJ, Tang WT, Long YK, Yang XH,
Ji XM, Yang JJ, Zhang RJ, Wang F, Shao JY and Du ZM: Smoking status
combined with tumor mutational burden as a prognosis predictor for
combination immune checkpoint inhibitor therapy in non-small cell
lung cancer. Cancer Med. 10:6610–6617. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mo J, Hu X, Gu L, Chen B, Khadaroo PA,
Shen Z, Dong L, Lv Y, Chitumba MN and Liu J: Smokers or
non-smokers: Who benefits more from immune checkpoint inhibitors in
treatment of malignancies? An up-to-date meta-analysis. World J
Surg Oncol. 18:152020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim JH, Kim HS and Kim BJ: Prognostic
value of smoking status in non-small-cell lung cancer patients
treated with immune checkpoint inhibitors: A meta-analysis.
Oncotarget. 8:93149–93155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
The R Core Team, . A Language and
Environment for Statistical Computing. R Foundation for Statistical
Computing; Vienna: 2024
|
|
16
|
Sjoberg DD, Whiting K, Curry M, Lavery JA
and Larmarange J: Reproducible summary tables with the gtsummary
package. R J. 13:570–594. 2021. View Article : Google Scholar
|
|
17
|
Terry Thernea, . A Package for Survival
Analysis in R. 2024.
|
|
18
|
Harrison E, Drake T and Pius R: Finalfit:
Quickly Create Elegant Regression Results Tables and Plots when
Modelling. 2025.
|
|
19
|
Kassambara A, Kosinski M and Biecek P:
Survminer: Drawing Survival Curves using ‘ggplot2’. 2024.PubMed/NCBI
|
|
20
|
Wickham H: ggplot2: Elegant Graphics for
Data Analysis. 2016.
|
|
21
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of Non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hobday SB, Brody RM, Kriegsman B, Basu D,
Newman J, Cohen RB, Lukens JN, Singh A, D'Avella CA and Sun L:
Outcomes among patients with mucosal head and neck squamous cell
carcinoma treated with checkpoint inhibitors. JAMA Otolaryngol Neck
Surg. 148:918–926. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu X, Liu Y, He Y, Wang Z, Zhang H, Yang W
and Lu J: Relationship between Patients' Baseline characteristics
and survival benefits in Immunotherapy-treated Non-small-cell lung
cancer: A systematic review and Meta-analysis. J Oncol.
2022:36019422022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gainor JF, Rizvi H, Jimenez Aguilar E,
Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon
C, Illei P, et al: Clinical activity of programmed cell death 1
(PD-1) blockade in never, light, and heavy smokers with
non-small-cell lung cancer and PD-L1 expression ≥50. Ann Oncol.
31:404–411. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Y, Yang Q, Shen J, Wei T, Shen W,
Zhang N, Luo P and Zhang J: The effect of smoking on the immune
microenvironment and immunogenicity and its relationship with the
prognosis of immune checkpoint inhibitors in Non-small cell lung
cancer. Front Cell Dev Biol. 9:7458592021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Desrichard A, Kuo F, Chowell D, Lee KW,
Riaz N, Wong RJ, Chan TA and Morris LGT: Tobacco Smoking-associated
alterations in the immune microenvironment of squamous cell
carcinomas. J Natl Cancer Inst. 110:1386–1392. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X, Ricciuti B, Nguyen T, Li X, Rabin
MS, Awad MM, Lin X, Johnson BE and Christiani DC: Association
between smoking history and tumor mutation burden in advanced
Non-small cell lung cancer. Cancer Res. 81:2566–2573. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fox P, Hudson M, Brown C, Lord S, Gebski
V, De Souza P and Lee CK: Markers of systemic inflammation predict
survival in patients with advanced renal cell cancer. Br J Cancer.
109:147–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Norum J and Nieder C: Tobacco smoking and
cessation, PD-L1 inhibitors in non-small cell lung cancer (NSCLC):
A review of the literature. ESMO Open. 3:e0004062018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luetragoon T, Rutqvist LE,
Tangvarasittichai O, Andersson BÅ, Löfgren S, Usuwanthim K and
Lewin NL: Interaction among smoking status, single nucleotide
polymorphisms and markers of systemic inflammation in healthy
individuals. Immunology. 154:98–103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shiels MS, Katki HA, Freedman ND, Purdue
MP, Wentzensen N, Trabert B, Kitahara CM, Furr M, Li Y, Kemp TJ, et
al: Cigarette smoking and variations in systemic immune and
inflammation markers. J Natl Cancer Inst. 106:dju2942014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu G, Li J, Zhang S, Cai J, Deng X, Wang Y
and Pei P: Two-dimensional nano-biomaterials in regulating the
tumor microenvironment for immunotherapy. Nano TransMed.
3:1000452024. View Article : Google Scholar
|
|
33
|
West H and Jin JO: Performance status in
patients with cancer. JAMA Oncol. 1:998. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McMillan DC: The systemic
inflammation-based glasgow prognostic score: A decade of experience
in patients with cancer. Cancer Treat Rev. 39:534–540. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wells M, Aitchison P, Harris F, Ozakinci
G, Radley A, Bauld L, Entwistle V, Munro A, Haw S, Culbard B and
Williams B: Barriers and facilitators to smoking cessation in a
cancer context: A qualitative study of patient, family and
professional views. BMC Cancer. 17:3482017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gritz ER, Toll BA and Warren GW: Tobacco
use in the oncology setting: Advancing clinical practice and
research. Cancer Epidemiol Biomarkers Prev. 23:3–9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scholten PR, Stalpers LJA, Bronsema I, van
Os RM, Westerveld H and van Lonkhuijzen LRCW: The effectiveness of
smoking cessation interventions after cancer diagnosis: A
systematic review and meta-analysis. J Cancer Policy.
39:1004632024. View Article : Google Scholar : PubMed/NCBI
|
